Vol 71, No 1 (2021)
Review paper
Published online: 2021-02-05

open access

Page views 777
Article views/downloads 566
Get Citation

Connect on Social Media

Connect on Social Media

SARS-CoV-2 infection: etiopathogenesis, clinical picture, current therapeutic options – the author’s observations

Krzysztof Simon12, Marta Rorat32, Justyna Janocha-Litwin12, Monika Pazgan-Simon12
Nowotwory. Journal of Oncology 2021;71(1):38-41.

Abstract

Currently, the scenario of a self-contained disappearance of the epidemic (as it was in the case of SARS) is no longer taken into consideration, whilst the SARS-CoV-2 virus will stay with us forever, similarly to other coronaviruses or flu. It is quite likely that periodical exacerbations of the epidemics – their growth and decrease – depend on many factors, which comprise, among others, the approval of the restrictions by the society or the manner in the epidemiological supervision is carried out and whether it is consistent. We must be ready for about 18–24 months of a high activity of COVID-19 with periodic active hot spots in many world regions. This requires efficient health services and the access to efficacious medication. Without an effective prophylactic vaccine, it seems that we will not be able to prevent the spread of the pandemic

Article available in PDF format

View PDF Download PDF file

References

  1. Zhu Na, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
  2. Kissler SM, Tedijanto C, Goldstein E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020; 368(6493): 860–868.
  3. Singhania N, Bansal S, Nimmatoori D, et al. Current Overview on Hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020; 20(5): 393–403.
  4. Pazgan-Simon M, Rorat M, Buczyńska I, et al. Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection. Pol Arch Intern Med. 2020; 130(4): 338–339.
  5. Szymanek-Pasternak A, Serafińska S, Kucharska M, et al. Severe course of coronavirus disease 2019 in a middle-aged man without risk factors. Pol Arch Intern Med. 2020; 130(4): 330–331.
  6. Flisiak R, Horban A, Jaroszewicz J, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Pol Arch Intern Med. 2020; 130(4): 352–357.
  7. Hongchao P, Peto R, Karim QA, et al. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. MedRxiv. (October 15 version).
  8. Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19): 1813–1826.
  9. Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 [Epub ahead of print].
  10. Li L, Zhang W, Hu Yu, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(5): 460–470.
  11. Martineau A, Jolliffe D, Hooper R, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017; 356: i6583.



Nowotwory. Journal of Oncology